...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
【24h】

Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.

机译：可切除的非小细胞肺癌中的肿瘤标志物CEA，NSE，SCC，TPA和CYFRA 21.1。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: In the last few years, several prognostic factors have been investigated in order to identify among patients with completely resected non-small cell lung cancer (NSCLC) subsets at high risk of recurrence. In this context, the actual role of serum tumour markers is still unclear. The aim of this study was to evaluate the prognostic significance of preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels in 62 patients submitted to radical surgery for non-small cell lung cancer (NSCLC). The predicting ability of these tumour markers with respect to histological type and pathological stage was also assessed. PATIENTS AND METHODS: After informed consent was obtained, the preoperative serum concentrations of the tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 were measured by means of immunometric assays in 62 patients referred to our Institutions from January to December 1992. All patients had resectable, histologically proven NSCLC and were submitted to radical surgery. Overall survival (OS) was calculated as the time elapsed from surgery to the date of death or last clinical evaluation; the prognostic effect of the tumour markers was investigated by Cox multiple regression models. RESULTS: Fifty-six patients were male and 6 female; median age was 62 years. Thirty-four patients had a histological diagnosis of adenocarcinoma and 28 of squamous cell carcinomas. With regard to pathological stage, 32 patients had stage I, 4 patients had stage II and 23 patients had stage IIIA disease. In this series of patients, at a median follow-up of 55 months after surgery, we found that both TPA and CYFRA 21.1 serum levels at the time of diagnosis were reliable predictors of overall survival high values of these markers being associated with worse prognosis. CONCLUSIONS: Our findings suggest that in completely resected NSCLC, TPA and CYFRA 21.1 preoperative serum levels might provide a useful tool for stratifying subgroups of patients with different chances of disease recurrence after surgery.
机译：背景：在过去的几年中，已研究了几种预后因素，以在患有完全切除的非小细胞肺癌（NSCLC）亚型的高复发风险患者中进行识别。在这种情况下，尚不清楚血清肿瘤标志物的实际作用。这项研究的目的是评估62例接受非小细胞肺癌（NSCLC）根治性手术的患者的术前CEA，NSE，SCC，TPA和CYFRA 21.1血清水平的预后意义。还评估了这些肿瘤标志物相对于组织学类型和病理阶段的预测能力。患者与方法：在获得知情同意后，通过免疫测定法对1992年1月至12月间转诊给我们机构的62例患者的肿瘤标志物CEA，NSE，SCC，TPA和CYFRA 21.1的血清浓度进行了测量。所有患者经组织学证实可切除的NSCLC并接受了根治性手术。总生存期（OS）是指从手术到死亡或最后一次临床评估所经过的时间。通过Cox多元回归模型研究了肿瘤标志物的预后。结果：56例患者中男6例。中位年龄为62岁。组织学诊断为腺癌的34例和鳞状细胞癌的28例。就病理分期而言，I期32例，II期4例，IIIA期23例。在这一系列患者中，在术后55个月的中位随访中，我们发现，诊断时TPA和CYFRA 21.1血清水平都是可靠的预测因素，表明这些标志物的总生存率高，与预后差有关。结论：我们的研究结果表明，在完全切除的NSCLC，TPA和CYFRA 21.1中，术前血清水平可能为分层不同手术后疾病复发机会的患者亚组提供有用的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号